BIOMAT Database Logo BIOMAT Database Logo

Interferon alpha-2b as therapy for patients with Ph'-positive chronic myelogenous leukemia. 1990

G Alimena, and E Morra, and M Lazzarino, and A M Liberati, and E Montefusco, and D Inverardi, and P Bernasconi, and M Mancini, and E Donti, and F Grignani
Department of Human Biopathology, University La Sapienza, Rome, Italy.

We treated 114 Ph'+ chronic myeloid leukemia (CML) patients, 105 of whom were in chronic phase (CP) and 9 in accelerated phase (AP), with interferon alpha-2b (IFN alpha-2b) at intermittent or daily doses of 2-5 MU/m2. Of 35 previously untreated CP patients, 22 (63%) showed complete hematological response (CHR). This was significantly influenced by initial risk status. In 19 of the 22 CHR patients the median of Ph'+ cells decreased from 100% to 58%. Of 36 patients pretreated for less than 12 months, 19 (53%) achieved CHR. CHR rate was significantly related to IFN dose. Cytogenetic improvement was observed in 15 of the 19 patients, the median of Ph'+ cells dropping from 100% to 76%, with complete suppression of the Ph' chromosome in 1 case. Of the 34 patients pretreated for greater than 12 months, 21 (62%) obtained CHR. Cytogenetic improvement was observed in 10 cases, the median of Ph'+ cells declining from 100% to 66%. 1 of 9 AP patients obtained CHR. After a median follow-up of 32 months for the 63 CHR patients, 49 (78%) are still in disease control: 34 on IFN therapy, 15 after bone marrow transplantation (BMT) (13 autologous and 2 allogeneic). Blastic transformation (BT) occurred in 9 of 63 (14%) CHR patients and in 24 of 51 (47%) patients with less than CHR. IFN alpha-2b has proved to be an effective treatment for CML. Its combination with other treatment modalities represents an interesting and promising approach for future studies.

UI MeSH Term Description Entries
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077190 Interferon alpha-2 Alpha interferon encoded by the human IFNA2 gene. Recombinant forms are used in the treatment of CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; KAPOSI SARCOMA; MELANOMA; and HAIRY CELL LEUKEMIA. IFN-alpha 2,IFN-alpha-2,IFNalpha-2b, Recombinant,Interferon alfa-2a,Interferon alfa-2b,Interferon alpha-2b, Recombinant,Interferon alpha-A,Interferon-alpha 2,Intron A (Interferon),LeIF A,Reaferon,Recombinant Interferon alpha-2a,Recombinant Interferon alpha-2b,Ro 22-8181,Roferon-A,Sch-30500,Viferon,IFNalpha 2b, Recombinant,Interferon alfa 2a,Interferon alfa 2b,Interferon alpha 2,Interferon alpha 2b, Recombinant,Interferon alpha A,Interferon alpha-2a, Recombinant,Recombinant IFNalpha-2b,Recombinant Interferon alpha 2a,Recombinant Interferon alpha 2b,Ro 22 8181,Ro 228181,Roferon A,RoferonA,Sch 30500,Sch30500
D015464 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS. Granulocytic Leukemia, Chronic,Leukemia, Granulocytic, Chronic,Leukemia, Myelocytic, Chronic,Leukemia, Myelogenous, Chronic,Leukemia, Myeloid, Chronic,Myelocytic Leukemia, Chronic,Myelogenous Leukemia, Chronic,Myeloid Leukemia, Chronic,Leukemia, Chronic Myelogenous,Leukemia, Chronic Myeloid,Leukemia, Myelogenous, Ph1 Positive,Leukemia, Myelogenous, Ph1-Positive,Leukemia, Myeloid, Ph1 Positive,Leukemia, Myeloid, Ph1-Positive,Leukemia, Myeloid, Philadelphia Positive,Leukemia, Myeloid, Philadelphia-Positive,Myelogenous Leukemia, Ph1-Positive,Myeloid Leukemia, Ph1-Positive,Myeloid Leukemia, Philadelphia-Positive,Chronic Granulocytic Leukemia,Chronic Granulocytic Leukemias,Chronic Myelocytic Leukemia,Chronic Myelocytic Leukemias,Chronic Myelogenous Leukemia,Chronic Myelogenous Leukemias,Chronic Myeloid Leukemia,Chronic Myeloid Leukemias,Granulocytic Leukemias, Chronic,Leukemia, Chronic Granulocytic,Leukemia, Chronic Myelocytic,Leukemia, Ph1-Positive Myelogenous,Leukemia, Ph1-Positive Myeloid,Leukemia, Philadelphia-Positive Myeloid,Leukemias, Chronic Granulocytic,Leukemias, Chronic Myelocytic,Leukemias, Chronic Myelogenous,Leukemias, Chronic Myeloid,Leukemias, Ph1-Positive Myelogenous,Leukemias, Ph1-Positive Myeloid,Leukemias, Philadelphia-Positive Myeloid,Myelocytic Leukemias, Chronic,Myelogenous Leukemia, Ph1 Positive,Myelogenous Leukemias, Chronic,Myelogenous Leukemias, Ph1-Positive,Myeloid Leukemia, Ph1 Positive,Myeloid Leukemia, Philadelphia Positive,Myeloid Leukemias, Chronic,Myeloid Leukemias, Ph1-Positive,Myeloid Leukemias, Philadelphia-Positive,Ph1-Positive Myelogenous Leukemia,Ph1-Positive Myelogenous Leukemias,Ph1-Positive Myeloid Leukemia,Ph1-Positive Myeloid Leukemias,Philadelphia-Positive Myeloid Leukemia,Philadelphia-Positive Myeloid Leukemias
D016898 Interferon-alpha One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells. In addition to antiviral activity, it activates NATURAL KILLER CELLS and B-LYMPHOCYTES, and down-regulates VASCULAR ENDOTHELIAL GROWTH FACTOR expression through PI-3 KINASE and MAPK KINASES signaling pathways. Interferon Alfa,Interferon, Leukocyte,Interferon, Lymphoblast,alpha-Interferon,IFN-alpha D,IFN-alpha5,Interferon alpha-1,Interferon alpha-17,Interferon alpha-4,Interferon alpha-5,Interferon alpha-7,Interferon alpha-88,Interferon alpha-J,Interferon alpha-T,Interferon alpha4,Interferon alpha5,Interferon, Lymphoblastoid,Interferon, alpha,LeIF I,LeIF J,Leif D,IFN alpha D,IFN alpha5,Interferon alpha,Interferon alpha 1,Interferon alpha 17,Interferon alpha 4,Interferon alpha 5,Interferon alpha 7,Interferon alpha 88,Interferon alpha J,Interferon alpha T,Leukocyte Interferon,Lymphoblast Interferon,Lymphoblastoid Interferon,alpha Interferon

Related Publications

G Alimena, and E Morra, and M Lazzarino, and A M Liberati, and E Montefusco, and D Inverardi, and P Bernasconi, and M Mancini, and E Donti, and F Grignani
Combination therapy with interferon alpha-2b plus low-dose interferon gamma in pretreated patients with Ph-positive chronic myelogenous leukaemia.
August 1992, British journal of haematology,
G Alimena, and E Morra, and M Lazzarino, and A M Liberati, and E Montefusco, and D Inverardi, and P Bernasconi, and M Mancini, and E Donti, and F Grignani
Juvenile chronic myelogenous leukemia: therapeutic trial with interferon alpha 2B.
September 1995, Indian pediatrics,
G Alimena, and E Morra, and M Lazzarino, and A M Liberati, and E Montefusco, and D Inverardi, and P Bernasconi, and M Mancini, and E Donti, and F Grignani
Interferon-alpha therapy for chronic myelogenous leukemia.
October 1995, The American journal of medicine,
G Alimena, and E Morra, and M Lazzarino, and A M Liberati, and E Montefusco, and D Inverardi, and P Bernasconi, and M Mancini, and E Donti, and F Grignani
[Interferon-alpha therapy in chronic myelogenous leukemia].
April 2000, [Rinsho ketsueki] The Japanese journal of clinical hematology,
G Alimena, and E Morra, and M Lazzarino, and A M Liberati, and E Montefusco, and D Inverardi, and P Bernasconi, and M Mancini, and E Donti, and F Grignani
Parkinsonism associated with interferon alpha therapy for chronic myelogenous leukemia.
March 2002, Hawaii medical journal,
G Alimena, and E Morra, and M Lazzarino, and A M Liberati, and E Montefusco, and D Inverardi, and P Bernasconi, and M Mancini, and E Donti, and F Grignani
Successful alpha-2b-interferon therapy for chronic neutrophilic leukemia.
August 1993, American journal of hematology,
G Alimena, and E Morra, and M Lazzarino, and A M Liberati, and E Montefusco, and D Inverardi, and P Bernasconi, and M Mancini, and E Donti, and F Grignani
Acral sclerosis due to interferon-alpha-2b in chronic myelogenous leukemia.
January 2002, Acta haematologica,
G Alimena, and E Morra, and M Lazzarino, and A M Liberati, and E Montefusco, and D Inverardi, and P Bernasconi, and M Mancini, and E Donti, and F Grignani
Interferon-alpha therapy for chronic myelogenous leukemia during pregnancy.
September 1998, American journal of hematology,
G Alimena, and E Morra, and M Lazzarino, and A M Liberati, and E Montefusco, and D Inverardi, and P Bernasconi, and M Mancini, and E Donti, and F Grignani
Acute pancreatitis associated with interferon alpha therapy for chronic myelogenous leukemia.
November 2000, Leukemia & lymphoma,
G Alimena, and E Morra, and M Lazzarino, and A M Liberati, and E Montefusco, and D Inverardi, and P Bernasconi, and M Mancini, and E Donti, and F Grignani
Multiple sclerosis associated with interferon-alpha therapy for chronic myelogenous leukemia.
June 2002, American journal of hematology,
Copied contents to your clipboard!